Intratracheal administration of mesenchymal stem cell-derived extracellular vesicles reduces lung injuries in a chronic rat model of bronchopulmonary dysplasia.
Administration, Inhalation
Animals
Animals, Newborn
Bronchopulmonary Dysplasia
/ complications
Disease Models, Animal
Extracellular Vesicles
/ physiology
Female
Hyperoxia
/ physiopathology
Lung Injury
/ etiology
Male
Mesenchymal Stem Cell Transplantation
/ methods
Mesenchymal Stem Cells
/ cytology
Pulmonary Alveoli
/ cytology
Pulmonary Artery
/ cytology
Rats
Rats, Sprague-Dawley
Trachea
bronchopulmonary dysplasia
exosomes
hyperoxia
rat
Journal
American journal of physiology. Lung cellular and molecular physiology
ISSN: 1522-1504
Titre abrégé: Am J Physiol Lung Cell Mol Physiol
Pays: United States
ID NLM: 100901229
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
pubmed:
28
1
2021
medline:
12
5
2021
entrez:
27
1
2021
Statut:
ppublish
Résumé
Early therapeutic effect of intratracheally (IT)-administered extracellular vesicles secreted by mesenchymal stem cells (MSC-EVs) has been demonstrated in a rat model of bronchopulmonary dysplasia (BPD) involving hyperoxia exposure in the first 2 postnatal weeks. The aim of this study was to evaluate the protective effects of IT-administered MSC-EVs in the long term. EVs were produced from MSCs following GMP standards. At birth, rats were distributed in three groups: (a) animals raised in ambient air for 6 weeks (
Identifiants
pubmed: 33502939
doi: 10.1152/ajplung.00148.2020
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM